413 related articles for article (PubMed ID: 24183742)
1. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
7. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
9. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
10. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
13. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
14. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
16. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
[TBL] [Abstract][Full Text] [Related]
18. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.
Carmi C; Galvani E; Vacondio F; Rivara S; Lodola A; Russo S; Aiello S; Bordi F; Costantino G; Cavazzoni A; Alfieri RR; Ardizzoni A; Petronini PG; Mor M
J Med Chem; 2012 Mar; 55(5):2251-64. PubMed ID: 22280453
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
[TBL] [Abstract][Full Text] [Related]
20. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
